Corvus Pharmaceuticals, Inc. (CRVS)
PHARMACEUTICAL PREPARATIONS
Corvus Pharmaceuticals, Inc. (CRVS) is listed on Nasdaq, where it has traded since March 23, 2016.
- Listed On
- Nasdaq
- Listed Since
- March 23, 2016
- Employees
- 37
- Market Cap
- $885M
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 166 institutions reported holding CRVS, with 70.4 million shares worth $1.1 billion in aggregate. The largest reported holder was Orbimed Advisors, with 7.2 million shares worth $107.0 million. Of the 5 largest holders listed below, 4 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Orbimed Advisors | 7,165,006 | $107M | Unchanged |
| BlackRock | 7,138,811 | $107M | Added 15.88% |
| Vanguard | 4,736,087 | $71M | Added 6.27% |
| State Street | 4,474,091 | $67M | Added 25.47% |
| T. Rowe Price | 3,789,126 | $57M | Added 29.88% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is CRVS?
Corvus Pharmaceuticals, Inc. (CRVS) is listed on Nasdaq, where it has traded since March 23, 2016.
Who are the largest institutional holders of CRVS?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of CRVS were Orbimed Advisors, BlackRock and Vanguard.
How many institutions own CRVS?
166 institutions reported a position in CRVS for the quarter ended June 30, 2026, worth $1.1 billion in total.
Did institutions buy or sell CRVS last quarter?
Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for CRVS.
Every reported institutional holder, plus insider and congressional trades in CRVS, on SentiSense.